Therefore, patients with RA who have not responded to traditional synthetic disease-modifying antirheumatic drugs (csDMARDs) may benefit from biologic therapies (BA), which include medications that block cytokines or their receptors, such as anti-TNF, anti-IL-1, and anti-IL-6 agents [4,5]. Here, TNF is linked to rheumatoid arthritis.